湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-069 第 1 页 共 11 页 湖南方盛制药股份有限公司 关于购买药品专利权的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 方盛制药拟以人民币 8,000 万元向中国药科大学、中国医学科学院药物研究所购买 化药 1 类创新药物 IMM-H024 原料药及制剂项目的专利权，后续将按相关约定节点分期付 款； 本次交易不构成关联交易，不构成重大资产重组；本次交易已经公司第六届董事会 2025 年第五次临时会议审议通过，无需提交股东会审议； 医药产品具有高科技、高风险、高附加值的特点，药品研发容易受到技术、审批、 政策等多方面因素的影响，药品审评审批时间、审批结果及未来产品市场竞争格局均存在诸 多不确定性。本次拟受让的专利权有两项正在申请中，这两项专利权能否取得以及最终取得 的时间均存在不确定性，敬请广大投资者谨慎决策，注意防范投资 ...

Group 1 - The company Fangsheng Pharmaceutical (603998.SH) plans to acquire the patent rights for the innovative chemical drug IMM-H024, including raw materials and formulations, for a total of RMB 80 million [1] - The acquisition will be made from China Pharmaceutical University and the Institute of Medicinal Research of the Chinese Academy of Medical Sciences [1] - Payment for the acquisition will be made in installments according to agreed milestones [1]

知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 数据来源：国家统计局，智研咨询整理 相关报告：智研咨询发布的《2025-2031年中国工业云行业市场深度评估及投资机会预测报告》 2025年1-5月，湖南省工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为21226 个，和上年同期相比，减少了202个，同比下降0.94%，占全国的比重为4.09%。 上市公司：株冶集团（600961），新威凌（871634），岳阳兴长（000819），克明食品（002661），盐 津铺子（002847），劲仔食品（003000），绝味食品（603517），华升股份（600156），千金药业 （600479），方盛制药（603998），泰嘉股份（002843），宇环数控（002903），宇晶股份 （002943 ...

Market Performance - A-shares major indices rose, with the Shenzhen Component Index increasing over 1%, the ChiNext Index rising over 1%, and the Shanghai Composite Index up by 0.44% [1] - Concepts such as liquid cooling, AI corpus, Huawei HiSilicon, shipbuilding, and film and television showed strong performance, while precious metals, coal, and multi-financial concepts weakened [1] - Nearly 4,000 stocks in the market rose, while 1,100 stocks declined [1] Stock Highlights - ST Xiangxue (300147) saw a price increase of 16.47% with a total market value of 5.892 billion [2] - Hanyu Pharmaceutical (300199) increased by 12.05%, with a market cap of 25.8 billion and a year-to-date increase of 126.53% [2] - Wanbangde (002082) rose by 10.01%, with a market value of 4.906 billion and a year-to-date increase of 24.73% [2] - Tian Shili (600535) increased by 7.73%, with a market cap of 26 billion and a year-to-date increase of 22.17% [2] - Shanghai Leifu (688091) rose by 6.94%, with a market value of 16.9 billion and a year-to-date increase of 104.93% [2] - Olin Bio (688319) increased by 5.63%, with a market cap of 10.3 billion and a year-to-date increase of 139.06% [2] - Yangguang Nuohuo (688621) rose by 5.22%, with a market value of 9.033 billion and a year-to-date increase of 114.56% [2] - Other notable stocks include Nuo Si Lan De (430047) up by 4.62%, Hai Te Bio (300683) up by 4.08%, and Nanxin Pharmaceutical (688189) up by 4.08% [2]

近日，在一家A股公司的独立董事补选中，候选人受到了两位董事的质疑。在他们看来，这位候选人年 龄较大且担任职务较多，可能难以适应公司高强度工作。 目前活跃在A股市场上的独董中，"高龄"者数量不少。证券时报记者在采访中了解到，在上市公司层 面，年龄并非其选任独董的关键考量因素。 回应"会尽全力" 8月7日，ST长园披露，独董丘运良因个人原因申请了辞职，公司董事会审议通过议案，同意提名关天 鹉为独董候选人，并将该事项提交公司2025年第四次临时股东大会审议。 在董事会投票时，ST长园董事邓湘湘、陈美川投了反对票。两人认为，上市公司目前处于内控整改完 善阶段，工作强度较大，考虑到候选人年龄较大且在多家公司担任职务的情况，建议审慎推选独董候选 人。 关天鹉出生于1958年，今年67岁，系注册会计师。2015年6月至今，他在佛山市中正诚会计师事务所从 事审计、评估工作。 关天鹉于2018年7月至今年7月，任海川智能独董；2022年7月至今，任科思科技独董。自2022年7月至 2025年5月，关天鹉还曾担任广东顺控城投置业、广东顺德科创管理集团、佛山市顺德区诚顺资产管理 等公司的董事。 据公开资料，ST长园现任三位独董张宇 ...

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Fangsheng Pharmaceutical, indicating a decline in revenue but an increase in net profit [1] - As of August 14, 2025, Fangsheng Pharmaceutical's stock closed at 11.05 yuan, down 1.78%, with a turnover rate of 4.24% and a trading volume of 186,300 hands, amounting to 209 million yuan [1] - The company's latest quarterly report shows total operating revenue of 418 million yuan, a year-on-year decrease of 4.62%, while net profit attributable to shareholders reached 88.26 million yuan, a year-on-year increase of 25.74% [1] Group 2 - The company has a current liquidity ratio of 0.829, a quick ratio of 0.511, and a debt-to-asset ratio of 44.14% [1] - Fangsheng Pharmaceutical has made investments in 42 enterprises and participated in 4,797 bidding projects, indicating active engagement in the market [2] - The company holds 115 trademark registrations and 62 patents, along with 170 administrative licenses, showcasing its intellectual property portfolio [2]

上市公司：株冶集团（600961），新威凌（871634），岳阳兴长（000819），克明食品（002661），盐 津铺子（002847），劲仔食品（003000），绝味食品（603517），华升股份（600156），千金药业 （600479），方盛制药（603998），泰嘉股份（002843），宇环数控（002903），宇晶股份 （002943），三德科技（300515），岱勒新材（300700），华锐精密（688059） 相关报告：智研咨询发布的《2025-2031年中国工业云行业市场深度评估及投资机会预测报告》 2025年上半年，湖南省工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为21242 个，和上年同期相比，减少了212个，同比下降0.99%，占全国的比重为4.08%。 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提 ...

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary, Guangdong Fangsheng Runkang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its innovative traditional Chinese medicine, Ziying Granules, aimed at treating chronic pelvic pain due to pelvic inflammatory disease [1] Company Summary - The Ziying Granules are designed to address symptoms such as lower abdominal pain, sacral distension, excessive yellow discharge, fluctuating low fever, and worsening menstrual pain [1] - The total research and development investment for this product has reached approximately 8.4717 million yuan [1] - As of now, the product has not been launched in domestic or international markets [1]

Group 1 - Kaipu Testing reported a revenue of 111 million yuan for the first half of 2025, a year-on-year increase of 3.23%, and a net profit of approximately 40.79 million yuan, up 3.73% year-on-year. The company plans to distribute a cash dividend of 3 yuan per 10 shares [1] - Chunguang Technology plans to invest no more than 1 billion yuan to build a new project with an annual production capacity of 8 million clean electrical products [1] - Fangsheng Pharmaceutical's subsidiary received approval for clinical trials of a traditional Chinese medicine, Ziying Granules, for chronic pelvic pain [2][3] Group 2 - Xintian Green Energy reported a power generation of 844,200 MWh in July 2025, a year-on-year increase of 9.32%, with a cumulative generation of 9,094,400 MWh, up 9.57% year-on-year [4][5] - Luvi Optoelectronics' controlling shareholder and major shareholders committed not to reduce their holdings for six months starting from August 18, 2025 [6][7] - Yunnan Energy Investment's subsidiary achieved grid-connected power generation for the first batch of wind turbines in the Yongning Wind Farm expansion project [9] Group 3 - Huizhi Microelectronics announced that a shareholder plans to reduce their stake by up to 1% [10] - Liyang Chip's shareholders plan to collectively reduce their holdings by up to 3.94% [11] - HeDa Technology's shareholder plans to reduce their stake by up to 1.0954% [12] Group 4 - *ST Sailong announced the resignation of its chairman and several senior executives due to a change in control [13] - Furan Energy's shareholder plans to reduce their stake by up to 0.37% [14] - Yinbao Shanneng's shareholder plans to reduce their stake by up to 1.54% [15] Group 5 - Silicon Treasure Technology's executives plan to reduce their holdings by up to 77,300 shares, representing 0.02% of the total share capital [16] - Henghua Technology's executive plans to reduce their stake by up to 9,280 shares, representing 0.015% of the total share capital [17] - Xingrui Technology's shareholders plan to reduce their holdings by up to 497,000 shares [18] Group 6 - Nanjing Julong's specific shareholder plans to reduce their stake by up to 0.87% [19][20] - Longlide's shareholder plans to reduce their stake by up to 1.9% [21] - Mengjie Co., Ltd.'s general manager plans to reduce their stake by up to 0.11% [22] Group 7 - Yuanda Holdings' vice chairman plans to reduce their stake by 80,000 shares, representing 0.16% of the total share capital [23] - Titan Co., Ltd. decided not to redeem its convertible bonds early despite meeting the redemption conditions [24] - Wantong Development plans to invest 854 million yuan to acquire a 62.98% stake in Shudao Technology [26][27]

Regulatory Environment - The China Securities Regulatory Commission (CSRC) will continue to tighten the entry standards for public offerings and will not allow large-scale expansions in the market [1] - The CSRC aims to cultivate long-term capital and establish a policy framework to support long-term investments [1] Economic Indicators - In July, the national consumer price index (CPI) remained flat year-on-year, with a month-on-month increase of 0.4% [2] Real Estate Policy - Beijing's housing authority announced new policies allowing families meeting certain criteria to purchase unlimited properties outside the Fifth Ring Road starting August 9, 2025 [3] - The maximum loan amount for second homes using public housing funds has increased from 600,000 to 1,000,000 yuan, with a minimum down payment ratio set at no less than 30% [3] Corporate Announcements - Industrial Fulian reported a 39% year-on-year increase in net profit for the first half of the year, with GB200 series products entering mass production [8] - Liou Co. plans to invest up to 3 billion yuan in securities [7] - Black Sesame announced that Guanglv Health intends to acquire a 20% stake, making it the controlling shareholder [14] Market Performance - Major U.S. stock indices saw collective gains, with the Dow Jones up 0.47%, Nasdaq up 0.98%, and S&P 500 up 0.78% [17] - Apple shares rose over 4%, marking a weekly increase of 13%, the best weekly performance since July 2020 [17] Corporate Developments - *ST Tianmao plans to voluntarily withdraw its A-share listing on the Shenzhen Stock Exchange [15] - The CSRC imposed a fine of 160 million yuan on *ST Gaohong for serious financial fraud, with potential delisting procedures initiated [16]